NewsBenzingaNektar Therapeutics Presents Data On Rezpegaldesleukin From Its Phase 2b REZOLVE-A, Phase 2b REZOLVE-AD Trials At European Academy Of Dermatology And Venereology Nektar Therapeutics Presents Data On Rezpegaldesleukin From Its Phase 2b REZOLVE-A, Phase 2b REZOLVE-AD Trials At European Academy Of Dermatology And Venereology Benzinga 2026.10.01 11:33 (GMT+0) Open on Benzinga Other news CZ warns: Be extra careful when visiting any website in the coming days BitGo launches innovation unit BitGo Labs, first focusing on the intersection of AI and crypto American Bankers Association criticizes OCC's new stablecoin rules: leaves a gap for third parties to pay yield Probability of Fed keeping rates unchanged in October at 83.9% Meta's personal AI agent Muse surpasses 10 million users one month after launch OpenAI backs stronger AI safety regulation in California
American Bankers Association criticizes OCC's new stablecoin rules: leaves a gap for third parties to pay yield
